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MEHDIRAD, A.A., FT A!..: Preliminary Clinical Results of a Unique Biphasic Waveform and an RV Lead
System. Biphasic defihrilhlion wavafonus have provided a reduction in defihrillation thrnsholds in
transvenous ICD systems. Although a variety of hiphasic waveforms have been tested, the optimal pulse
durations and tilts have yet to he identified. A niulticenter clinical study was conducted to evaluate the
performance of a new ICD hiphasic waveform and new HV active fixation steroid ehiting lead system.
Fifty-three patients were entered into the study. Mean age was 63 years with a mean ejection fraction of
36.8%. Primary indication for implantation was monomorphic ventricular tachycardia alone (54.7%).
Forty-eight patients (90.6%) were implanted with an RV shocking lead and active can alone as the anodal
contact. The ICD can was the cathode. In four cases (7.5%), an additional SVC or CS had was used due
to a high DFT with the liV lead alone. In an additional case, a chronic SVC lead was used although the
HV-Can DFT was acceptable. DFT for all cases at implant was 9.8 ± 3.7 f. Repeat testing at 3 months for
a subset of patients showed a reduction in DFT (7.4 ± 3.0 }}, P value = 0.03. Sensing and pacing charac-
teristics of the HV lead system remained excellent during the study period (acute 0.047 ± 0.005 msat 5.4
V and 9,9 ± 6.2 mV R wave; chronic 0.067 ±0.11 msat 5.4 V and 9.3 ± 5.4 mV R wave). It is concluded
that this lead system provides good acute and chronic sensing and pacing characteristics with good DFT
values in combination with this waveform. (PACE 1999; 22lPt.I]594-599).
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Introduction
The use of implantable cardioverter defibril-
lator (ICD) technology in humans began with large
abdominal implants using epicardial patches.^ Al-
though the therapy was shown to he extremely ef-
fective, the requiromtmt for a thoracotomy proce-
dure to place the patch electrodes limited tho
clinical applicability. As the technology ad-
vanced, more advanced pectorally implanted de-
vices with transvenous lead systems became
available,^"^ Such advancements have now led to
widespread clinical use of the ICD.
It is well accepted that some biphasic wave-
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forms can decrease the defibrillation threshold
(DFT) compared to monophasic wave forms. "̂ -̂
The shape and efficacy of biphasic waveforms can
be altered by several factors including pulse am-
plitude, tilt, and durations. Studies in animal
models and humans have demonstrated that some
special biphasic waveforms can decrease DFT
compared to other biphasic waveforms or a
monophasic waveform,''~'* however the optimal
biphasic waveform has yet to be identified in re-
gard to pulse durations and tilt. This multicenter
study evaluated a new biphasic waveform used
with a new steroid eluting endocardial defibrilla-




The study population included 53 success-
fully implanted patients. The mean age of the
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study population was 63.0 ± 14.7 years. There
were 39 men in the group (73.6%). Mean ejection
fraction was 36.8% ± 15.0% with a range of
13%-82%. There were 14 patients (26.4%) who
were classified New York Heart Association
(NYHA) Class I, 29 patients (54.7%) were Class II,
and 9 patients (17.0%) were Class III. There were
no patients identified as Class IV. In one case, data
was not reported. Reported indications for implan-
tation of the ICD included: monomorphic ventric-
ular tachycardia (VT) alone (29 patients [54.7%]);
monomorphic VT and ventricular fibrillation (VF)
(5 patients [9.4%]); Polymorphic VT alone (3 pa-
tients [5.7%!); polymorphic VT and VF (1 patient
[1.9%]); and VF alone (15 [28.3%]). The underiy-
ing cardiac disease was reported to be ischemic
cardiomyopathy in 17 patients (32.1%), di]ated
cardiomyopathy in 11 patients (20.8%). combina-
tion of coronary artery disease and dilated car-
diomyopathy in 9 patients (17.0%), hypertrophic
cardiomyopathy in 3 patients (5.7%), valvular
heart disease in 2 patients (3.8%), other cardiomy-
opathies in 5 patients (9.4%). and not reported in
6 patients (11.3%). In 4 patients (7.5%), an existing
pacemaker system was in place. Fourteen patients
(26.4%) were on amiodarone and 6 patients
(11.3%) on sotalol. Twenty patients (37.8%) were
taking one cardioactive drug, and 16 patients
(30.2%) were taking two cardioactive drugs. There
were 17 patients (32.1%) on no cardioactive drugs.
Waveform Description
The biphasic waveform was incorporated in a
new implantable ICD under clinical investigation
(Aegis Model 2600, Pacesetter). The waveform is
produced using 95 ^iF capacitance (2 190 |xF capac-
itors in series). Phase 1 of the waveform has a max-
imal leading edge voltage of 750 V with an initial tilt
of 44% (Fig. 1). Following the 44% decay of the
leading edge voltage, Phase 1 is extended another
1.6 ms before truncation. With typical shocking lead
impedances, this provides a Phase 1 duration of ap-
proximately 4.5-5.0 ms. The leading edge voltage of
Phase 2 is equa] to the trailing edge of Phase 1. The
duration of Phase 2 is fixed at 2.5 ms.
Defibrillation Lead Description
The Model 1559 lead system is a single endo-









Figure 1. Biphasic wavefonii with 44% tilt followed by
a fixed 1.6 ms extension in phase 1. Phase 2 is a fixed
2.5 ms pulse duration. Leading edge of phase 2 equals
the trailing edge of phase 1.
right ventricular (RV) apex. The tip has an ex-
tendible/retractable screw that has a stimulating
surface area of 8.5 mm^. Within the helix assembly
is a silicone matrix plug that incorporates 1 mg
dexamethasone phosphate for gradua] steroid elu-
tion. A ring electrode for true hipolar sensing ca-
pability is positioned 1 cm proximal from the tip
and has a surface area of 34 mm". Both the tip and
ring electrodes are coated with a titanium nitride
material to increase porosity, reduce polarization,
and optimize sensing characteristics. The shock-
ing coil is positioned 2.4 cm from the distal tip
and is 5.0 cm in length. Total surface area of the
shocking electrode is 459 mm^. The lead body is
constructed of silicone rubber and has a diameter
of 10 Fr. The two conductors for the tip and ring
electrodes and the single shocking conductor are
separately insulated within the lead body hy sili-
cone rubber. The rate sensing terminal is a stan-
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dard IS-1 connector and Ihe high voltage connec-
tor is DF-1. Lead lengths are 58. 85, and 100 cm.
The ICD physical dimensions were 8.1 cm
wide. 6.3 cm high, and 1.6 cm thick providing a
total volume of 60 cc. The weight of the device
was 110 g.
Study Design
The clinical trial included 14 participating
centers in the U.S. and Europe. The study protocol
required lead system electrical testing that in-
cluded pacing thresholds and sensing amplitudes
at implantation, predischarge from the hospital
(typically the next day), and 1, 3, and B months
postimplantation. Pacing and sensing values were
determined hoth with external testing systems
(PSA and DSA) and the ICD at the time of implan-
tation. DFTs were measured at the time of device
implantation using an external Defibrillation Sys-
tem Analyzer (DSA) and emulator can (Model
2670 DSA and model 2674 emulator. Pacesetter),
that simulated the implanted device. The external
system was used to allow control of the time from
induction to shock for all patients. This provided
hetter control for DFT measurements. The DFT
was measured using a single step down protocol
beginning at 600 V (17.1 J) and stepping down by
100 V increments. When failure to defibrillate was
observed, the next test shock was increased by 50
V. The DFT was then determined hy the lowest en-
ergy test shock that resulted in successful conver-
sion of the rhythm. If successful, conversion was
observed at 4.2 J. further testing to identify the
DFT was not required. Repeat testing of DFT was
repeated at the 3 month follow-up at the discre-
tion ofthe investigator and patient. This data col-
lection was not requinjd and was therefore only
collected on a subset of patients.
Statistical Analysis
A Student's paired f-test was used to compare
acute and chronic DFT and sensing thresholds ob-
tained in the "true" and "integrated" bipolar sens-
ing configurations. A P value of < 0.05 was con-
sidered significant.
Results
All 53 patients received the model 1559 RV
defibrillation lead. The lead was typically im-
planted on the loft side (49 patients. 92.5%) with
the left sLibciavian vein predominately used (37
patients. 69.8%). The lead was inserted via the
cephalic vein in the remaining 12 patients (22.6%)
who had implants on the left side. Only three sys-
tems (5.7%) were implanted on the right side (1
cephalic and 2 subclavian). In one case, the ve-
nous entry was not reported. Mean capture thresh-
old at implant using an external pacing system an-
alyzer (PSA) was 0.7 ± 0.3 V (0.1-1.8) using a 0.5
ms pulse duration. Capture threshold was deter-
mined from the tip to the RV coil electrode as this
was the configuration used by the implanted ICD
for pacing. Moan pulse duration capture threshold
using the DSA and implanted device was 0.065 ±
0.09 and 0.047 ± 0.005 ms. respectively, at a fixed
voltage of approximately 5.4 V. As the device can
be programmed to sense either "true" bipolar or
"integrated" bipolar, both configurations were
tested at implant. "True" hipolar use.s both the tip
and anodal band electrodes for sensing (tip-ring).
"Integrated"hipolaruses the tip and defihrillation
coil as the electrode pair (tip-coil). The mean R
wave amplitude at implant for the tip-ring config-
uration ranged from 14.2-9.9 mV depending on
the test method (PSA. DSA. or implanted ICD).
Tip-coil configuration ranged from 11.6-4.6 mV.
The tip-ring configuration provided statistically
higher signals for all three test systems using the
paired data (Table I).
In 48 patients (90.6%). only the RV lead was
implanted with the device. In these cases, the
shocking configuration was RV coil ( + ) to device
can (-). In 4 patients, a second transvenous lead
was required due to an elevated DFT witb the sin-
Table I.
Comparison of Implantation R Wave Measurements
Between Tip-Ring ("True" Bipolar) and Tip-Coil















DSA = detibrillation system analyzer: PSA = pacing system
analyzer
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gle RV lead to can configuration. In three ofthe.se
cases a second shocking electrode was placed in
the superior vena cava (SVC), and in one case, it
was placed in the coronary sinus. In the final pa-
tient, there was an existing chronic SVC lead that
was therefore utilized clinically. However, the RV
to can configuration alone provided acceptable
thresholds in this case.
The mean DFT at implant for all shocking con-
figurations was 9.8 ± 3.71 (4.2-17.1). The DFT was
9.4 ± 3.6 J for RV-can alone and 14.4 ± 2.2) for RV-
SVC (or CS)-can. The mean first shock impedance
for Ihe clinical settings was 53.5 ± 10.8 Q.
Sensing and capture thresholds on the defib-
rillation lead system remained stable during the
chronic follow-up period. At the time of last fol-
low-up, the R wave sensing amplitude (tip-ring)
was 9.3 ± 5.4 mV (n = 42) as compared to the ini-
tial value through the implanted device of 9.9 ±
6.2 m V (n = 55). The R wave amplitude for the tip-
coil configuration at last follow-up was 5.6 ± 2.2
mV (n = 3) as compared to 4.6 ± 2.8 mV (n - 54)
at implant. Capture threshold at last follow-up us-
ing the implanted device was 0.067 ± 0.11 ms at
5.4 V as compared to 0.047 ± 0.005 ms at 5.4 V at
implant.
Twelve patients had their DFT retested at the
3 month follow-up. Eleven of these patients
showed the same or lower DFT at 3 months (Fig.
2). For the 12 patients, the mean implantation DFT
was 9.8 ± 3.0 I and tbe mean DFT at the 3 month
Defibrillation TfireslioTas
3 Months
Figure 2. Paired defibriUation threshold data for 12
palienls. There is a statistical reduction in threshold at
3 months.
follow-up was 7.4 ± 3.0 J. These values were
shown to be statistically different (P = 0.03).
Discussion
Biphasic wavefonns can lower DFTs compared
to monophasic waveforms. Development of an opti-
mal biphasic waveform shotild address many vari-
ables including capacitance, pulse durations, tilt,
and amplitude of each phase.
The new waveform described differs from
conventional biphasic waveforms in three areas:
capacitance value, phase 1 duration, and phase 2
duration. The capacitor value is reduced to 95 fi,F
as compared to other ICD's using 125-180 ixF. This
change will increase the average current in phase 1
and give a duration of the primary phase close to
the chronaxie. theoretically lowering the DFT.̂ **"'̂
Several studies bave demonstrated this relation-
ship in animals'̂ "^** and humans.'''"^' The phase 1
duration is defined as a moderate tilt (44%) fol-
lowed by a 1.6 ms extension. This provides a hy-
brid approach to the fixed tilt (which may over-
compensate for impedance changes) and the fixed
duration (which has no compensation).''' The
phase 2 duration was fixed at 2.5 ms based on the
"burping" theory that the function of pbase 2 is to
reduce the residual transmembrane potential from
the phase 1 shock.̂ ''•^^
In addition to sensing and pacing, the electri-
cal performance of the ICD lead system can have
an impact on the DFT. In our study, the electrical
performance of the new lead system was found to
be excellent during the 6 month study period.
Sensing and capture thresholds remained clini-
cally stable, possibly due to the steroid elution ca-
pability. However, a nonsteroid version ofthe lead
was not prospectively compared.
Acute DFTs were found to be low and were
seen to be significantly reduced at 3 months. Al-
though the sample size in this study was small,
the DFT results were favorable as compared to a
larger reported study.^^ In that study of 473 pa-
tients, the mean acute DFT was 11.4 ) with a re-
ported 3 month DFT of 9.9 J. In this limited study,
the acute DFT was 9.8 J and 3 month DFT was 7.4
J. Due to the lack of randomization to other leads
and waveforms in the study design, the level of
contribution ofthe new waveform or new lead to
the low DFT cannot be determined.
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Questions regarding the sensing performance
of integrated bipolar systems bave been raised be-
fore.^^"^^ In this limited study, the paired implan-
tation data statistically revealed a reduction in the
R wave amplitude for the integrated bipolar sys-
tem. Tbese measurements were made during nor-
mal sinus rhythm and not following a shock. Fur-
ther degradation of the signal might have been
seen postshock for the integrated bipolar system.
Conclusion
It is concluded that this new hiphasic wave-
form provided a low acute and chronic DFT
within this limited population. The sensing and
pacing characteristics were also good and re-
mained chronically stable. The steroid elution fea-
ttire may have provided this benefit, but further
prospectively randomized studies are needed.
Participating centers in this clinical trial in-
cluded: The Ohio State University. Columbus. OH
(A. Mehdirad. M.D.); Tbe Mayo Clinic. Rochester.
MN (M. Stanton. M.D.); University of Michigan
Hospitals. Ann Arbor. MI (S.A. Strickherger.
M.D.); Allegheny University, Philadelphia. PA (S.
Kutalek. M.D.); Methodist Hospital. Lubbock. TX
(G. Wells, M.D.); Sacred Heart Hospital. Eugene.
OR (M. Antimisiaris, M.D.); St. Vincent's Hospital,
Indianapolis, IN (E. Prystowsky. M.D.); University
Hospital. Lucerne. Switzerland (R. Cardinas.
M.D.); Na Homoloce. Prague. Czech Republic (M.
Taborsky, M.D.); Sequoia Hospital. Redwood City,
CA (H. Mead. M.D.): Luzern Hospital. Lucerne.
Switzerland (P. Erne. M.D.): Michigan Capital
Hospital. East Lansing. MI (R.K. Thakur. M.D.); St.
Francis Hospital. Roslyn. NY (J. Levine, M.D.):
and Huntington Memorial Hospital. Pasadena. CA
(M. Meyers. M.D.).
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